Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.4.4 (
kinesin
)
5,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Deficiency of caytaxin results in hereditary ataxia or dystonia in humans, mice and rats. Our yeast two-hybrid screen identified
kinesin
light chains (KLCs) as caytaxin-binding proteins. The tetratricopeptide-repeat region of KLC1 recognizes the ELEWED sequence (amino acids 115-120) of caytaxin. This motif is conserved among
BNIP-2
family members and other KLC-interacting
kinesin
cargo proteins such as calsyntenins. Caytaxin associates with
kinesin
heavy chains (KHCs) indirectly by binding to KLCs, suggesting that caytaxin binds to the tetrameric
kinesin
molecule. In cultured hippocampal neurons, we found that caytaxin is distributed in both axons and dendrites in punctate patterns, and it colocalizes with microtubules and KHC. GFP-caytaxin expressed in hippocampal neurons is transported at a speed ( approximately 1 mum/second) compatible with
kinesin
movement. Inhibition of
kinesin
-1 by dominant-negative KHC decreases the accumulation of caytaxin in the growth cone. Caytaxin puncta do not coincide with vesicles containing known
kinesin
cargos such as APP or JIP-1. A part of caytaxin, however, colocalizes with mitochondria and suppression of caytaxin expression by RNAi redistributes mitochondria away from the distal ends of neurites. These data indicate that caytaxin binds to
kinesin
-1 and functions as an adaptor that mediates intracellular transport of specific cargos, one of which is the mitochondrion.
...
PMID:Cayman ataxia protein caytaxin is transported by kinesin along neurites through binding to kinesin light chains. 1986 99
The Cdo-p38MAPK (p38 mitogen-activated protein kinase) signaling pathway plays important roles in regulating skeletal myogenesis. During myogenic differentiation, the cell surface receptor Cdo bridges scaffold proteins
BNIP-2
and JLP and activates p38MAPK, but the spatial-temporal regulation of this process is largely unknown. We here report that KIF5B, the heavy chain of
kinesin
-1 motor, is a novel interacting partner of
BNIP-2
. Coimmunoprecipitation and far-Western study revealed that
BNIP-2
directly interacted with the motor and tail domains of KIF5B via its BCH domain. By using a range of organelle markers and live microscopy, we determined the endosomal localization of
BNIP-2
and revealed the microtubule-dependent anterograde transport of
BNIP-2
in C2C12 cells. The anterograde transport of
BNIP-2
was disrupted by a dominant-negative mutant of KIF5B. In addition, knockdown of KIF5B causes aberrant aggregation of
BNIP-2
, confirming that KIF5B is critical for the anterograde transport of
BNIP-2
in cells. Gain- and loss-of-function experiments further showed that KIF5B modulates p38MAPK activity and in turn promotes myogenic differentiation. Of importance, the KIF5B-dependent anterograde transport of
BNIP-2
is critical for its promyogenic effects. Our data reveal a novel role of KIF5B in the spatial regulation of Cdo-
BNIP-2
-p38MAPK signaling and disclose a previously unappreciated linkage between the intracellular transporting system and myogenesis regulation.
...
PMID:KIF5B transports BNIP-2 to regulate p38 mitogen-activated protein kinase activation and myoblast differentiation. 2537 81
BNIP-2
shows high homology with the Cayman ataxia protein, caytaxin, which functions as a
kinesin
-1 adapter bridging cargos and
kinesin
light chains (KLCs).
BNIP-2
is known to induce cell shape changes when over-expressed in culture cells, but its physiological functions are mostly unknown.
BNIP-2
interacts with KLC through the conserved WED motif in the N-terminal region of
BNIP-2
. Interaction with KLC and transportation by
kinesin
-1 are essential for over-expressed
BNIP-2
to elongate cells and induce cellular processes. Endogenous
BNIP-2
localizes to the Golgi apparatus, early and recycling endosomes and mitochondria, aligned with microtubules, and moves at a speed compatible with
kinesin
-1 transportation. The CRAL-TRIO domain of
BNIP-2
specifically interacts with phosphatidylserine, and the vesicular localization of
BNIP-2
requires interaction with this phospholipid.
BNIP-2
mutants which do not bind phosphatidylserine do not induce morphological changes in cells. These data show that similar to caytaxin,
BNIP-2
is a
kinesin
-1 adapter involved in vesicular transportation in the cytoplasm and that association with cargos depends on interaction of the CRAL-TRIO domain with membrane phosphatidylserine.
...
PMID:BNIP-2 binds phosphatidylserine, localizes to vesicles, and is transported by kinesin-1. 2547 45
Microtubules display dynamic turnover during cell migration, leading to cell contractility and focal adhesion maturation regulated by Rho guanosine triphosphatase activity. This interplay between microtubules and actomyosin is mediated by guanine nucleotide exchange factor (GEF)-H1 released after microtubule depolymerization or microtubule disconnection from focal adhesions. However, how GEF-H1 activates Rho upon microtubule disassembly remains elusive. Here, we found that
BNIP-2
, a BCH domain-containing protein that binds both RhoA and GEF-H1 and traffics with
kinesin
-1 on microtubules, is important for GEF-H1-driven RhoA activation upon microtubule disassembly. Depletion of
BNIP-2
in MDA-MB-231 breast cancer cells decreases RhoA activity and promotes cell migration. Upon nocodazole-induced microtubule disassembly, the interaction between
BNIP-2
and GEF-H1 increases, while knockdown of
BNIP-2
reduces RhoA activation and cell rounding via uncoupling RhoA-GEF-H1 interaction. Together, these findings revealed that
BNIP-2
couples microtubules and focal adhesions via scaffolding GEF-H1 and RhoA, fine-tuning RhoA activity and cell migration.
...
PMID:BNIP-2 retards breast cancer cell migration by coupling microtubule-mediated GEF-H1 and RhoA activation. 3278 68